Evening Primrose Oil (GLA).

EPA slows delta-5 desaturase, so DGLA made from evening primrose GLA is retained rather than converted onward to arachidonic acid. The pairing shifts the eicosanoid balance toward the series-1 arm.

Evening primrose oil is roughly three quarters linoleic acid with about a tenth as GLA. The GLA portion is the delta-6 desaturase product that bypasses the slowest step in the chain.

The oil is highly unsaturated and needs a chain-breaking antioxidant to hold its fatty acid profile. Tocopherol is the standard inclusion in every evening primrose softgel.

Ascorbate regenerates oxidised tocopherol at the lipid and water interface. That recycling keeps a small vitamin E dose working across a large polyunsaturated pool.

Delta-6 desaturase depends on zinc status to convert linoleic acid into GLA. Adequate zinc keeps the endogenous route working alongside the preformed GLA in the oil.

Cholecalciferol requires dietary lipid to form micelles for uptake. An evening primrose softgel supplies that lipid in the same swallow.

Astaxanthin absorbs several fold better with an oil carrier. Once in the membrane it also slows peroxidation of the polyunsaturated fatty acids around it.

GLA-derived prostaglandin E1 lowers normal platelet aggregation while ginkgolides antagonise platelet activating factor. Both act on the same physiology and the effect adds.

Garlic organosulfur compounds reduce normal platelet aggregation on their own. Combined with a GLA oil the two effects stack.

Nattokinase works on fibrin while GLA works through platelets. Together they touch both arms of normal clot formation.

Magnesium is a required cofactor for the desaturase and elongase steps that carry gamma-linolenic acid onward to dihomo-gamma-linolenic acid. Supplying preformed GLA bypasses the first desaturation but not the downstream handling. This is a cofactor relationship read from established biochemistry, not a combination trial.

Pyridoxal 5-phosphate supports the desaturase and elongase activity involved in converting essential fatty acids along the omega-6 chain. Low B6 status limits that machinery regardless of how much substrate arrives. Cofactor logic, not an outcome claim.

Riboflavin becomes FAD, which the cytochrome b5 reductase feeding fatty acid desaturases depends on for electron transfer. Without that flavin-dependent step the desaturase system runs poorly. The link is biochemical rather than clinical.

NADH supplies the reducing equivalents for microsomal fatty acid desaturation, and niacin sets NAD pool size. The relationship is upstream and general, so this row is mechanistic support rather than evidence for a combined effect.

EPA restrains delta-5 desaturase, the step that would convert dihomo-gamma-linolenic acid to arachidonic acid. Taken with a GLA source, that tends to hold more of the DGLA pool at DGLA. This is a substrate-flux argument about lipid pools, which are markers and not outcomes.

DHA and gamma-linolenic acid enter the same desaturase and elongase pipeline from opposite ends, omega-3 and omega-6. Co-supplementation shifts membrane fatty acid composition in both series at once. Composition is what shifts; any downstream effect needs its own evidence.

Krill oil contributes phospholipid-bound EPA and DHA alongside the omega-6 GLA in evening primrose oil, so the two together broaden the fatty acid pool rather than duplicating it. Formulators pair them for that reason. No combination trial of the specific pair is cited here.

Alpha-linolenic acid from flaxseed and linoleic acid from evening primrose oil compete for the same delta-6 desaturase. A large ALA load slows omega-6 desaturation and the same is true in the other direction. Because evening primrose oil already carries preformed GLA, the competition matters more for its linoleic acid fraction.

Isolated GLA and evening primrose oil deliver the same fatty acid, so stacking them is dose addition rather than a new mechanism. Label reading matters here because total GLA intake is what changes. Worth flagging so intake is counted once.

Glutathione peroxidases are selenoenzymes that reduce lipid hydroperoxides formed from polyunsaturated fatty acids. Adequate selenium status is part of how the body handles a larger polyunsaturated load. This is protective biochemistry, not an efficacy claim for the pair.

Tocotrienols act as chain-breaking antioxidants in the lipid phase, interrupting peroxidation of polyunsaturated fatty acids in the oil and in membranes. Oil manufacturers add vitamin E family compounds for exactly this reason. The endpoint is oxidative stability of the lipid, a chemical measure.

Pancreatic lipase hydrolyses the triglycerides of evening primrose oil to free fatty acids and monoglycerides before uptake. Where lipase output is low, fat absorption is the limiting step for any oil. Supplemental lipase addresses that step, not the fatty acid itself.

Bile salts emulsify dietary oil into micelles so lipase can work and the products can cross the enterocyte membrane. People with reduced bile flow absorb oils less completely. Textbook lipid digestion rather than a studied combination.

Broad-spectrum enzyme blends include lipase and are taken with fat-containing supplements for the same digestive reason. The benefit is on the digestion step, which is a process measure. Nothing here says the pair changes any clinical endpoint.

Lecithin is a phospholipid emulsifier used to disperse oils in aqueous formats and in emulsions. It changes how the oil presents to the gut, not what the fatty acid does. Common formulation practice, described not ranked.

Phosphatidylcholine supplies both a phospholipid vehicle and choline, and its fatty acid tails draw on the same pool that GLA feeds into. Pairing it with an omega-6 oil is a delivery choice. The interaction is on lipid handling.

Rosemary extract is used as a lipid-phase antioxidant to slow peroxide formation in cold-pressed oils during shelf life. Its role is on the oil in the bottle rather than on physiology. A stability measure, not a health effect.

Biotin is the cofactor for acetyl-CoA carboxylase, which sets the malonyl-CoA supply used by the elongases that extend gamma-linolenic acid. The connection is upstream and non-specific. Listed as cofactor context, not as evidence for a pair.

Medium-chain triglycerides are absorbed by a partly separate route and are often used as a carrier oil for softgels and liquids. They can serve as the vehicle without contributing to the omega-6 pool. Formulation context only.

Large calcium loads in the gut lumen form insoluble soaps with free fatty acids, which reduces the fraction absorbed. That is why high-dose mineral and oil doses are often separated by a couple of hours. The effect is on absorption efficiency.

Salicylate-containing willow bark and omega-6 fatty acid supplementation both act on platelet function, so the effects can stack. A trial of omega-3 or omega-6 supplementation in postmenopausal women reported reduced platelet reactivity as a laboratory marker. Anyone already using an agent that affects clotting should raise this with a clinician.

Borage seed oil and evening primrose oil are both sold on their gamma-linolenic acid content, at different declared shares of total fat. Taken together they add GLA to the same pool and they load the same enzymatic step. Anyone stacking them is raising total GLA rather than adding a second mechanism.

Marine oils and evening primrose oil pull on the same desaturase and elongase machinery from the n-3 and n-6 sides. Reported work has given the two together and measured circulating inflammatory markers. Markers moved in that report; a marker is not a clinical outcome.

Mixed tocopherols are added to polyunsaturated oils to slow chain oxidation during shelf life. In an evening primrose softgel the tocopherol is protecting the oil, not delivering a separate nutritional action. It is a formulation dependency and reads as one.

Lecithin emulsifies an oil phase, which matters for emulsions, chewables and liquid formats rather than for a plain softgel. It aids dispersion of the oil in aqueous gut contents. This is a manufacturing role and no absorption number is claimed here.

Gingerols have been described as affecting platelet aggregation in laboratory assays. Combined with a GLA source that also feeds platelet eicosanoid pathways, the direction of effect adds rather than opposes. Confidence stays low because this is mechanism and assay work, not a trial of the pair.

Curcuminoids are described as acting on cyclooxygenase and lipoxygenase branches of eicosanoid metabolism, the same branches that handle DGLA and arachidonic acid. Formulators pair them for that reason. The grounding is in vitro and mechanistic, so the row stays at early confidence and off the badge.